Aubier M
Service de Pneumologie, INSERM U408, Paris.
Rev Pneumol Clin. 1996;52(2):145-9.
Bronchial inflammation is an almost constantly encountered feature in asthma, even in early stages. Corticosteroid therapy has been shown to be effective both in reducing bronchial inflammation and improving signs of bronchial hyperreactivity. The possible side effects of prolonged inhaled corticosteroids cannot be ignored. Thus, while the indication for inhaled corticosteroids is severe asthma is clear, many questions are raised in case of intermittent minor asthma. There is still much debate over the correct initial dose (high or low) and the clinical and functional criteria for dose reduction or withdrawal. We discuss here the modalities for starting and stopping inhaled corticosteroids in patients with asthma.
支气管炎症几乎是哮喘中始终存在的特征，即使在早期阶段也是如此。皮质类固醇疗法已被证明在减轻支气管炎症和改善支气管高反应性体征方面均有效。长期吸入皮质类固醇的潜在副作用不容忽视。因此，虽然吸入皮质类固醇用于重度哮喘的指征很明确，但对于间歇性轻度哮喘则引发了许多问题。关于正确的初始剂量（高剂量或低剂量）以及减量或停药的临床和功能标准仍存在诸多争议。我们在此讨论哮喘患者开始和停用吸入皮质类固醇的方式。
